Predictors of mortality among HIV infected children on anti-retroviral therapy in Mekelle Hospital, Northern Ethiopia: a retrospective cohort study

BMC Public Health

Carla Decotelli¹  Berhe Weldearegawi²  Fisaha Haile²  Solomon Gebremariam²  Aregay Gebremedhin³ 

[1] General Manager of Corporate Health at Vale, Vale, Brazil;College of Health Sciences Department of Public Health, Mekelle University, Mekelle, Ethiopia;Tigray Regional Health Bureau, Mekelle, Ethiopia

关键词: Ethiopia;    Survival;    HAART;    HIV;    Children;   

Others  :  1161579
DOI  :  10.1186/1471-2458-13-1047

 received in 2012-12-05, accepted in 2013-10-31,  发布年份 2013

【 摘 要 】

Background

The introduction of antiretroviral therapy in 1996 improved the longevity and wellbeing of peoples living with HIV in the industrialized world including children. This survival benefit of antiretroviral therapy (ART) in reducing HIV related deaths has been well studied in the developed world. In resource-poor settings, where such treatment was started recently, there is inadequate information about impact of ART on the survival of patients especially in children. So, this study aims to investigate predictors of mortality of children on ART. Therefore, the objective of this study was to identify predictors of mortality among children on HAART.

Methods

A retrospective cohort study was conducted on 432 children who initiated antiretroviral therapy from June 2006 to June 2011 at pediatrics ART clinic in Mekelle Hospital, Northern-Ethiopia. Data were extracted from electronic and paper based medical records database and analyzed using Kaplan Meier survival and Cox proportional hazard model to identify independent predictors of children’s mortality on ART.

Results

The total time contributed by the study participants were 14,235 child-months with median follow up of 36 months. The mortality rate of this cohort was 1.40 deaths per 1000 child-months or 16.85 deaths per 1000 child-years. Age less than 18 months [ Adj.HR (95% CI) = (4.39(1.15-17.41)], CD4 percentage <10 [Adj.HR (95% CI) = 2.98(1.12-7.94)], WHO clinical stage (III&IV) [Adj.HR (95% CI) = 4.457(1.01-19.66)], chronic diarrhea[Adj.HR (95% CI) = 4.637(1.50-14.31)] and hemoglobin < 8 g/dl[Adj.HR (95% CI) = 3.77(1.29-10.98)] all at baseline were significantly and independently associated with survival of children on ART.

Conclusions

Mortality of children on ART was low and factors that affect mortality of children on ART were age less than 18 months, lower CD4 percentage, advanced WHO clinical stage (III&IV), presence of chronic diarrhea and lower hemoglobin level all at baseline. The high early mortality rate would support the value of an earlier treatment start before development of signs of immunodeficiency syndrome despite the method of HIV diagnosis and WHO stage.

【 授权许可】

   
2013 Gebremedhin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]WHO: Prevention of Mother-To-Child Transmission (PMTCT). Briefing Note Department of HIV/AIDS. 2007. Available at: http://www.who.int/hiv/pub/toolkits/PMTCT%20HIV%20Dept%20brief%20Oct%2007.pdf webcite. Accessed December 2011
• [2]Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE: Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008., 8(52) doi:10.1186/1471-2334-8-52
• [3]WHO/UNAIDS/UNICEF: Towards universal access and Scaling up priority HIV/AIDS interventions in the health sector, Progress Report. 2011. Available at: http://www.unicef.org/eapro/Towards_Universal_Access_on_HIVAIDS.pdf webcite. Accessed January 2012
• [4]Federal HIV/AIDS prevention and control office Federal ministry of health (FMOH, FHAPCO): Guidelines for implementation of the antiretroviral therapy programme in Ethiopia. 2000. Available at: http://www.ilo.org/wcmsp5/groups/public/---ed_protect/---protrav/---ilo_aids/documents/legaldocument/wcms_125385.pdf webcite. Accessed February 2012
• [5]Federal Democratic Republic of Ethiopia Federal HIV/AIDS Prevention and Control Office: Report on progress towards implementation of the UN Declaration of Commitment on HIV/AIDS. 2010. Available at: http://data.unaids.org/Pub/report/2010/ethiopia_2010_country_progress_report_en.pdf webcite. Acesssed March 2012
• [6]Abrams E, El-Sadr W, Rabkin M: The Pediatric Clinical Manual; the International Center for AIDS Programs. 2004. Available at: http://www.medbox.org/preview/5255d0fa-3e6c-41db-af3f-7b560e695ecc/doc.pdf webcite. Accessed December 2011
• [7]WHO: Antiretroviral therapy for HIV infection in infants and children. Towards universal access, Recommendations for a public health approach. 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf webcite. Accessed March 2012
• [8]Foca M, Moye J, Matthews Y, Rich K, Luzuriaga EHK, et al.: Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV. Pediatrics 2006., 118(146) doi:10.1542/peds.2005-0294
• [9]Eley B, Nuttall J, Davies MA, Smith L, Cowburn C, H , et al.: Initial experience of a public-sector antiretroviral treatment programme for HIV-infected children and their infected parents. S Afr Med J 2004, 94(8):643-646.
• [10]Ellis J, Molyneux EM: Experience of anti-retroviral treatment for HIV-infected children in Malawi, the 1st 12 months. Ann Trop Paediatr 2007, 27(4):261-267.
• [11]Statistics/Data Analysis V. 11.1 Stata Corp, Lakeway Drive College Station. Texas USA; 2009. Available at: http://www.stata.com/manuals13/mi.pdf webcite. Accessed at January 2012
• [12]Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA, et al.: Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. JAIDS 2007, 45(3):311-317.
• [13]Wamalwa DC, Obimbo EM, Farquhar C, Richardson BA, Mbori-Ngacha DA, Inwani I, et al.: redictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya. BMC Pediatr 2010., 10(33) doi:10.1186/1471-2431-10-33
• [14]Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC: Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999, 180(3):666-672.
• [15]European Collaborative Study: Level and pattern of HIV-1-RNA viral load over and differences between girls and boys? AIDS 2002, 16(1):97-104.
• [16]Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME: Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa. PLoS One 2011., 6(7) doi:10.1371/journal.pone.0022706
• [17]Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al.: Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, south Africa. BMC Pediatric 2007., 7(13) doi:10.1186/1471-2431-7-13
• [18]Bong CN, Yu JK, Chiang HC, Huang WL, Hsieh TC, Schouten EJ: Risk factors for early mortality in children on adult fixed-dose combination antiretroviral therapy in a central hospital in Malawi. AIDS 2007, 21(13):1805-1810.
• [19]Yotebieng M, Van Rie A, Moultrie H, Cole SR, Adimora A, Behets F: Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS 2010, 24(9):1341-1349.
• [20]Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al.: Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359(21):2233-2244.
• [21]Hosmer DW, Lemeshow S, May S: An Introduction to the Counting Process Approach to Survival Analysis, in Applied Survival Analysis: Regression Modeling of Time-to-Event Data. Second edition. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2008.
• [22]Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, et al.: Clinical outcomes and CD4 response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007, 298(16):1888-1899.
• [23]Janssen N, Ndirangu J, Newell ML, Bland RM: Successful paediatric HIV treatment in rural primary care in Africa. Arch Dis Child 2010, 95(6):414-421.
• [24]Callens SF, Shabani N, Lusiama J, Lelo P, Kitetele F, Colebunders R: Mortality and associated factors after initiation of pediatric antiretroviral. Pediatr Infect Dis J 2009, 28(1):35-40.
• [25]Fetzer BC, Hosseinipour MC, Kamthuzi P, Hyde L, Bramson B, Jobarteh K: Predictors for mortality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Malawi. Trop Med Int Health 2009, 14(8):862-869.
• [26]Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot-Olupot P, et al.: Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS 2008, 22(18):2493-2499.
• [27]Sutcliffe CG, van Dijk JH, Munsanje B, Hamangaba F, Sinywimaanzi P, Thuma PE, et al.: Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia. BMC Infect Dis 2011., 11(54) doi:10.1186/1471-2334-11-54
• [28]World Health Organization Anthro Plus. Geneva, Switzerland; 2007. Available at: http://www.who.int/growthref/tools/who_anthroplus_manual.pdf webcite. Acessed April 2012
• [29]Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C: Long-term survival and immune-virologic response of African HIV-1 infected children to highly active antiretroviral therapy regimens. AIDS 2006, 20(18):2315-2319.
• [30]Koye DN, Ayele TA, Zeleke BM: Predictors of mortality among children on Antiretroviral Therapy at a referral hospital, Northwest Ethiopia: a retrospective follow up study. BMC Pediatr 2012, 12:161. doi:10.1186/1471-2431-12-161 BioMed Central Full Text
• [31]Taye B, Shiferaw S, Enquselassie F: The impact of malnutrition in survival of HIV infected children after initiation of antiretroviral treatment (ART) in Zewditu memorial hospital, Addis Ababa. Ethiopia. Ethiop Med J 2010, 48(1):1-10.
• [32]Asfawesen GY, Solomie J, Bisirat T, Berhanu GM, Mebratu B, Rahlenbeck S: Outcome in a paediatric cohort receiving ART in Addis Abeba. Ethiopia Acta Paediatr 2011, 100(8):1164-1167.
• [33]Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M: Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. J Acquir Immune Defic Syndr 2010, 54(5):524-532.
• [34]Walker AS, Mulenga V, Ford D, Kabamba D, Sinyinza F, Kankasa C: The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 2007, 44(10):1361-1367.